Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)
Launched by TAMPERE UNIVERSITY HOSPITAL · Feb 12, 2021
Trial Information
Current as of August 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Altogether 14.000 1995-1997 born women resident in communities where herd effect against high-risk HPV infections was created with gender-neutral vaccination of birth cohorts 1992-1995 (A-communities) or not (control C-communities) in 2007-2010 with the bi-valent HPV16/18 vaccine will be invited to participate a randomized screening trial at the ages of 25 and 28 years.
Cervical samples will be analysed for HPV DNA with MGP (Modified General Primer) primer system followed by MALDITOF(matrix assisted laser desorption ionization-time of flight mass spectrometry) mass spectrometry on the SEQU...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Born 1995-1997. 25 years of age residence in one of the eight community-randomized trial A communities with documented herd effect from gender-neutral vaccination or C communities devoid of the herd effect.
- Exclusion Criteria:
- • Immune compromising disease status (e.g. transplant recipients). HPV vaccination
About Tampere University Hospital
Tampere University Hospital (TAYS) is a leading academic medical center in Finland, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, TAYS integrates cutting-edge medical practices with rigorous scientific investigation, focusing on improving patient outcomes and enhancing treatment modalities across various specialties. The hospital collaborates with a network of researchers, healthcare professionals, and academic institutions to foster a multidisciplinary approach to medical research, ensuring that findings are translated into real-world applications for the benefit of patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, , Finland
Hämeenlinna, , Finland
Iisalmi, , Finland
Joensuu, , Finland
Jyväskylä, , Finland
Kemi, , Finland
Kotka, , Finland
Kouvola, , Finland
Kuopio, , Finland
Lahti, , Finland
Oulu, , Finland
Pori, , Finland
Porvoo, , Finland
Rauma, , Finland
Sastamala, , Finland
Seinäjoki, , Finland
Tampere, , Finland
Varkaus, , Finland
Patients applied
Trial Officials
Matti Lehtinen, MD, PhD
Principal Investigator
Tampere University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials